AFSTYLA 250 IU

Dosage

Children: Refer to specific drug information for paediatric dosing guidelines, as this will also vary.

Adults: Refer to specific drug information for dosing guidelines, as this will vary widely.

Mechanism of action

The mechanism of action for 'alfa' cannot be defined without specific identification of the drug. Each compound named 'alfa' will have distinct mechanisms, typically involving receptor interaction, enzyme inhibition, or modulation of physiological pathways.

Pharmacodynamics

Pharmacodynamics will vary widely depending on the specific agent referred to as 'alfa'. Generally, pharmacodynamics describes how a drug affects the body, including its therapeutic effects, side effects, and the relationship between drug concentration and effect.

Pharmacokinetics

The pharmacokinetics of 'alfa' would also depend on the particular drug profile, including absorption, distribution, metabolism, and excretion (ADME). Parameters such as bioavailability, half-life, and clearance rates would need to be defined based on the specific agent.

Pregnancy

Consult healthcare provider for risk assessment.

Breast-feeding

Consult healthcare provider for risk assessment.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Treatment and prevention of bleeding episodes in patients with Hemophilia A
• Perioperative management in patients with Hemophilia A

Dosage

Children: Refer to specific pediatric dosing guidelines or consult the BNF for Children for dosing recommendations.

Adults: Refer to specific prescribing guidelines or consult the BNF for dosing recommendations in adults.

Mechanism of action

Lonoctocog functions as a replacement therapy for factor VIII, which is essential for the normal clotting process. Upon administration, lonoctocog binds to von Willebrand factor and is activated in the presence of factor IXa. This activation leads to the conversion of factor X to Xa, ultimately resulting in thrombin generation and fibrin formation. This mechanism restores the coagulation pathway and helps to control or prevent bleeding episodes.

Pharmacodynamics

The pharmacodynamics of lonoctocog involves its role in enhancing hemostasis in patients with Hemophilia A. It increases the levels of factor VIII in circulation, which is directly correlated with improved clotting ability. The clinical effect is dose-dependent, and its efficacy can be monitored through laboratory assessments of factor VIII activity and clinical observation of bleeding episodes.

Pharmacokinetics

Lonoctocog exhibits a half-life that allows for less frequent dosing compared to older factor VIII products. After intravenous administration, it is distributed throughout the plasma, and its elimination follows a biphasic pattern. The drug is primarily cleared by proteolytic degradation and is not significantly metabolized by the liver or excreted by the kidneys. This pharmacokinetic profile contributes to its effectiveness in managing bleeding episodes in hemophilia patients.

Contra-indications

• Hypersensitivity to the active substance or to any of the excipients
• Severe liver dysfunction
• Active thromboembolic disease

Adverse effects

• Allergic reactions
• Infusion-related reactions
• Headache
• Nausea
• Dizziness
• Fatigue
• Joint pain

Interactions

• Other anticoagulants may increase the risk of bleeding
• Concomitant use with other factor replacement therapies should be managed carefully

Precautions

• Monitor for signs of thromboembolic events
• Evaluate liver function before and during treatment
• Use with caution in patients with known risk factors for thromboembolism

Pregnancy

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Limited data on the use in pregnant women.

Breast-feeding

It is not known whether lonoctocog is excreted in human milk. Caution should be exercised when administering to nursing women.

Storage

Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light. Once reconstituted, use as soon as possible.

Formulations

• Powder for solution for injection